Prof. Dr. Scott McNeil is the Head of the Nanopharmaceutical and Regulatory Science Group within the Department of Pharmaceutical Sciences at the University of Basel. He received his B.S. degree in Chemistry from Portland State University and his Ph.D. in Cell Biology and Anatomy from Oregon Health Sciences University. Scientists within his group develop and characterize novel nano-based formulations, with the goal of improving the therapeutic index of active pharmaceutical ingredients. Prof. McNeil’s research involves Regulatory Science topics in nanomedicine and using nanomedicines to deliver enzymes for the treatment of lysosomal storage diseases. In collaboration with other research institutions, the Group also identifies and investigates the critical quality attributes (CQAs) of nanopharmaceuticals and nanosimilars, such as mechanisms of action, safety, and practical application issues. Prior to joining the University of Basel in 2020, he was the Director of the Nanotechnology Characterization Laboratory (NCL) at the National Cancer Institute. In addition to his academic career, McNeil served for twenty years in the US Army.